Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Xin Dong(Shanghai University), Yuzhuo Wang(BC Cancer Agency), Wan L. Lam(University of British Columbia), Calum MacAulay(BC Cancer Agency), John C. English(BC Cancer Agency), Nevin Murray(BC Cancer Agency), Victor Ling(BC Cancer Agency), Kenneth G. Evans(BC Cancer Agency), Janessa Laskin(BC Cancer Agency), Julia Flint(BC Cancer Agency), Peter W. Gout(BC Cancer Agency), John Yee(BC Cancer Agency), Jun Guan(Qingdao University), Raymond T. Ng(University of British Columbia), Stephen Lam(University of British Columbia)
Cited by 195
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Near‐infrared Raman spectroscopy for optical diagnosis of lung cancer
|International Journal of Cancer|2003|811
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Identifying Individuals with Physcian Diagnosed COPD in Health Administrative Databases
|COPD Journal of Chronic Obstructive Pulmonary Disease|2009|664
Identifying Patients with Physician‐Diagnosed Asthma in Health Administrative Databases
|Canadian Respiratory Journal|2009|439